Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Ardsley Partners Further Trims Stake in Saba Software, Inc. (SABA)

Philip Hempleman‘s Ardsley Partners reported selling some of its Saba Software, Inc. (OTCMKTS:SABA) holding. The fund disposed a total of 15,000 shares, trimming the position to around 3.31 million shares. The securities have been sold in one deal, the price amounting to $12.36 per share.

Saba Software, Inc. (NASDAQ:SABA)

Overall, in several transactions during the fourth quarter of 2013, Ardsley Partners sold around 61,600 shares of Saba Software, Inc. (OTCMKTS:SABA).

Philip Hempleman’s Ardsley Partners had earlier sold 17,300 shares of Saba Software, Inc. (OTCMKTS:SABA).

In December, Saba Software, Inc. (OTCMKTS:SABA) a global leader in next-generation cloud solutions for talent management, joined Cloud Security Alliance (CSA) a not-for-profit organization that aims provide security assurance within cloud computing. Earlier the company had also announced about its new recruiting offering, Recruiting@Work, to bring objectivity into hiring decisions.

The company managed to add 203 new customers in fiscal 2013 representing a 44% increase over 141 new customers in the fiscal 2012.

Philip Hempleman’s Ardsley Partners initiated a position in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) and bought 1.93 million shares representing 5.7% of the company’s common stock.

Philip Hempleman’s Ardsley Partners, a long/short equity hedge fund, has approximately $1 billion under management. The fund invests in value stocks that are growth oriented and has an inclination towards chemical and chemical-related companies.

Ardsley Partners’ equity portfolio contains Jazz Pharmaceuticals plc (NASDAQ:JAZZ), with 423,500 shares, worth $38.95 million. The second largest holding, in terms of value, is United Rentals, Inc. (NYSE:URI), Ardsley owning 654,300 shares, valued at $38.14 million shares. Another company where the fund has invested a 7.02% of its portfolio is Canadian Solar Inc. (NASDAQ:CSIQ) with 2.03 million shares worth $34.41 million.

Disclosure: none

Recommended Reading:

Blue Mountain Capital Decreases Stake in Lexmark International Inc (LXK)

Pershing Square Increases Stake in Howard Hughes Corp (HHC)

Steven Cohen Opens Position in E-House (China) Holdings Limited (ADR) (EJ)

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!